
## AMD Center of Excellence® Wellness Model



Will you recommend protective lenses?\_\_\_\_\_



## AMD Staging, Treatment and Management Guidelines

|   | Subclinical AMD   | Early AMD   | Intermediate AMD  | Advanced AMD   |
|---|---|---|---|--|
| Functional<br>Testing<br>(Average Rod<br>Intercept <sup>1</sup> ) | <b>RI ≥ 6.5</b><br>The diagnostic<br>specificity and<br>sensitivity of the 6.5<br>minute cut-point for<br>the presence of AMD<br>is greater than 90%  |   | <b>16.6</b> (+/- 5.2)<br>orrelated with disease severity.<br>ng AMD severity based on thes  |  |
| Structural<br>Imaging   | <ul> <li>No drusen or small<br/>drusen ≤ 63 μm</li> <li>No pigmentary<br/>abnormalities</li> </ul>  | <ul> <li>Medium drusen &gt; 63<br/>μm and ≤ 125 μm</li> <li>No pigmentary<br/>abnormalities</li> </ul>  | <ul> <li>1 large druse &gt; 125<br/>µm and/or</li> <li>Pigmentary<br/>abnormalities</li> </ul>  | <ul> <li>Geographic atrophy<br/>(GA)<br/>or</li> <li>Choroidal<br/>neovascularization<br/>(CNV)</li> </ul> |
| Treatment<br>Guidelines <sup>2</sup>                              | <ul> <li>Prescribe smoking cessation program</li> <li>Prescribe nutritional supplementation</li> <li>Discuss lifestyle modifications with respect to diet and exercise</li> <li>Discuss systemic disease management</li> <li>Prescribe blue light protection</li> <li>Prescribe UVA and UVB protection</li> </ul> | <ul> <li>Monitor smoking<br/>cessation compliance</li> <li>Monitor nutritional<br/>supplementation</li> <li>Review diet and<br/>exercise regimen</li> <li>Partner with primary<br/>care provider on<br/>systemic disease<br/>management</li> <li>Check blue light<br/>protection</li> <li>Reinforce UVA and<br/>UVB protection</li> </ul> | <ul> <li>Monitor smoking<br/>cessation compliance</li> <li>Review vitamin<br/>and supplement<br/>recommendations</li> <li>Discuss diet and<br/>exercise regimen</li> <li>Manage systemic<br/>diseases with<br/>primary care<br/>provider</li> <li>Re-evaluate optical<br/>protection</li> </ul> | <ul> <li>Low vision<br/>rehabilitation<br/>for GA</li> <li>Anti-VEGF injections<br/>for CNV</li> </ul>     |
| Frequency of<br>Exams   | Every 6-12 months<br>to monitor for rapid<br>progression with<br>clinical exam, imaging<br>and dark adaptation<br>testing   | <b>Every 6 months</b> to<br>monitor for rapid<br>progression with<br>clinical exam, imaging<br>and dark adaptation<br>testing   | <b>Every 3-6 months</b> to<br>monitor for CNV with<br>clinical exam, imaging<br>and dark adaptation<br>testing  | Refer to Retina<br>Specialist at first sign<br>of CNV or GA  |

1. Jackson, G. R., Scott, I. U., Kim, I. K., Quillen, D. A., Iannaccone, A., & Edwards, J. G. (2014). Diagnostic Sensitivity and Specificity of Dark Adaptometry for detection of Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science, 55, 1427–1431.

2. Practical Guidelines for the Treatment of AMD, published as a supplement to Review of Optometry in October, 2017

